+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cervical Dystonia - Pipeline Insight, 2020

  • PDF Icon

    Clinical Trials

  • 106 Pages
  • February 2020
  • Region: Global
  • DelveInsight
  • ID: 4989321
Cervical Dystonia Overview

Cervical Dystonia Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Cervical Dystonia market. A detailed picture of the Cervical Dystonia pipeline landscape is provided, which includes the disease overview and Cervical Dystonia treatment guidelines. The assessment part of the report embraces in-depth Cervical Dystonia commercial assessment and clinical assessment of the Cervical Dystonia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical Dystonia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Cervical Dystonia of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Cervical Dystonia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Cervical Dystonia treatment.
  • Cervical Dystonia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Cervical Dystonia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Cervical Dystonia Analytical Perspective

In-depth Cervical Dystonia Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Cervical Dystonia Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Cervical Dystonia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cervical Dystonia across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Cervical Dystonia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Cervical Dystonia research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cervical Dystonia .

Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Cervical Dystonia .
  • In the coming years, the Cervical Dystonia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Cervical Dystonia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Cervical Dystonia treatment market. Several potential therapies for Cervical Dystonia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Cervical Dystonia market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Cervical Dystonia ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions
  • What are the current options for Cervical Dystonia treatment?
  • How many companies are developing therapies for the treatment of Cervical Dystonia?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Cervical Dystonia?
  • How many Cervical Dystonia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Cervical Dystonia?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Cervical Dystonia market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Cervical Dystonia?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Cervical Dystonia therapies?
  • What are the clinical studies going on for Cervical Dystonia and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Cervical Dystonia?
  • How many patents are granted and pending for the emerging therapies for the treatment of Cervical Dystonia?

Table of Contents

1. Report Introduction
2. Cervical Dystonia
2.1. Overview
2.2. History
2.3. Cervical Dystonia Symptoms
2.4. Causes
2.6. Cervical Dystonia Diagnosis
2.6.1. Diagnostic Guidelines
3. Cervical Dystonia Current Treatment Patterns
3.1. Cervical Dystonia Treatment Guidelines
4. Cervical Dystonia - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Cervical Dystonia companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary
4.1.2. Cervical Dystonia Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Cervical Dystonia Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA Assessment by Stage and MOA
5.1.6. Assessment by Target Assessment by Stage and Target
6. Cervical Dystonia Late Stage Products (Phase-III)7. Cervical Dystonia Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. Cervical Dystonia Discontinued Products
13. Cervical Dystonia Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description Product Overview Mechanism of action
13.1.2. Research and Development Clinical Studies
13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail
13.1.4. Tabulated Product Summary General Description Table
14. Cervical Dystonia Key Companies15. Cervical Dystonia Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Cervical Dystonia Unmet Needs18. Cervical Dystonia Future Perspectives19. Cervical Dystonia Analyst Review20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Revance Therapeutics, Inc.
  • Syneos Health
  • Ipsen
  • Medy-Tox
  • Hugel